头部药企再涉诉,这一次它如何应对?

投资时报
18 Sep 2024

针对艾伯维的指控,百济神州予以否认,并表示将坚决捍卫自身知识产权标点财经、投资时间网研究员 卓玛国家药品监督管理局药品审评中心(CDE)官网公示信息显示,知名创新药企业百济神州有限公司(下称百济神州,688235.SH,06160.HK,BGNE.O)申报的1类新药BGB-58067片的临床试验申请获得受理。据百济神州公开资料显示,BGB-58067是一款PRMT5抑制剂,为该公司的实体瘤在研产品...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10